行业周报：减重新靶点初显锋芒，小核酸疗法前景可期-20260111

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The pharmaceutical and biotechnology sector has shown a positive trend, with a 7.81% increase in early January 2026, outperforming the CSI 300 index by 5.03 percentage points [8][34] - Arrowhead's small RNA therapies ARO-INHBE and ARO-ALK7 have demonstrated promising early clinical data for obesity treatment, indicating a potential new era in weight management therapies [6][15][24] Summary by Sections Industry Performance - The pharmaceutical and biotechnology sector has risen by 7.81% in the first week of January 2026, ranking 6th among 31 sub-industries [8][34] - The hospital sector experienced the highest increase at 13.92%, while the traditional Chinese medicine sector had the lowest increase at 2.89% [37] Clinical Data Insights - ARO-INHBE showed a 9.9% average reduction in visceral fat at week 16 in a single-agent treatment for obesity with T2DM, with a 37.8% reduction in liver fat compared to baseline [6][15] - In combination therapy with Tirzepatide, ARO-INHBE achieved nearly double the weight loss effect compared to Tirzepatide alone, with significant reductions in total fat and visceral fat [7][16] - ARO-ALK7 demonstrated an 88% average degradation rate of ALK7 mRNA, with a 13.6% reduction in visceral fat, indicating superior efficacy compared to ARO-INHBE [24][29] Market Positioning - There is an accelerated focus on the INHBE and ALK7 targets by domestic and international companies, with several products entering clinical stages [31][33] - The competitive landscape for ALK7 is relatively favorable, with fewer products in clinical stages compared to INHBE, which has multiple candidates in development [31][33]